https://doi.org/10.3390/ijms241411791Breast CancerGenentech takes over Regor’s RGT-419B for US$850m upfrontGenentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company’s breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics’ … more ➔
Spima TherapeuticsPartnershipSpima Therapeutics starts with global licence agreementSPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001 more ➔
GourmeyNovel FoodEFSA updates guidelines on cultured proteins and Novel FoodThe EU’s food watchdog EFSA has updated its guidelines for novel food applications including cell-based and fermented foods to streamline approval times and clarify that food safety is its highest priority … more ➔
Ovid Therapeutics - Jeremy LevinStatementLong version of The BIOSECURE Act: The West’s Wake-Up Call to China’s Biotech DominanceBy Jeremy Levin, D.Phil, MB BChir more ➔
Asabys PartnersFinancingAsabys Partners close €180m Sabadell Asabys II Fund Asabys Partners have announced the closing of a new oversubscribed fund aimed at investing in 12-15 companies across all areas of pharma biotech. more ➔
SR-TigitFinancingGenespire raises US$52m in Series B roundItalian SR-Tiget spin out Genespire srl will use the proceeds of a €46.6m (US$52m) Series B financing to advance its paediatric in-vivo gene therapy for the rare metabolic disorder Methylmalonic Acidemia … more ➔
Image by freepikAMRAMR Accelerator urges long-term fundingAntimicrobial resistance (AMR) poses a huge threat to the prevention and treatment of a growing number of infections caused by bacteria, parasites, viruses, and fungi. A public-private partnership involving … more ➔
CDC/Phil_ImagesVaccinesVicebio Ltd cashes in US$100m in Series B financingLondon-based Vicebio Ltd has announced a US$100m Series B financing that will support Phase I testing of its bivalent RSV vaccine candidate VXB-241 and pushing development of another pipeline progra … more ➔
Brenus Pharma SAFinancingFrench Brenus AS closes US$25m financingFrench Brenus Pharma SA has raised €22.2m (US$25m) to accelerate clinical trials of two precision cancer vaccines derived from tumour cell banks representing more than 200 tumour antigens. more ➔
UE 2024 - PEEU Von der Leyen names new EU CommissionersEuropean Commission President Ursula von der Leyen has revealed her nominees for new commissioners to lead the bloc for the next term from 2024 to 2029. more ➔
https://doi.org/10.3390/ijms241411791
Spima Therapeutics
Gourmey
Ovid Therapeutics - Jeremy Levin
Asabys Partners
SR-Tigit
Image by freepik
CDC/Phil_Images
Brenus Pharma SA
UE 2024 - PE